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Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death, especially in
China. And the mechanism of its progression remains poorly understood. Growing evidence indicates that long
non-coding RNAs (lncRNAs) are found to be dysregulated in many cancers, including HCC. CDKN2B antisense
RNA1 (ANRIL), a lncRNA, coclustered mainly with p14/ARF has been reported to be dysregulated in gastric
cancer, esophageal squamous cell carcinoma, and lung cancer. However, its clinical significance and potential
role in HCC is still not documented.
Methods and results: In this study, expression of ANRIL was analyzed in 77 HCC tissues and matched normal
tissues by using quantitative real-time polymerase chain reaction (qRT-PCR). ANRIL expression was up-regulated in HCC
tissues, and the higher expression of ANRIL was significantly correlated with tumor size and Barcelona Clinic Liver
Cancer (BCLC) stage. Moreover, taking advantage of loss of function experiments in HCC cells, we found that
knockdown of ANRIL expression could impair cell proliferation and invasion and induce cell apoptosis both
in vitro and in vivo. We also found that ANRIL could epigenetically repress KLF2 transcription in HCC cells
by binding with PRC2 and recruiting it to KLF2 promoter region. We also found that Sp1 could regulate the
expression of ANRIL.
Conclusion: Our results suggest that lncRNA ANRIL, as a growth regulator, may serve as a new biomarker
and target for therapy in HCC.
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Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related death globally. Half of these
deaths were estimated to occur in China [1]. The prog-
nosis of patients with HCC remains poor despite the
therapeutic advances in HCC treatment recently. There-
fore, a great challenge lies ahead in the understanding of
the molecular mechanisms of hepatocarcinogenesis and
the identification of the new biomarkers for HCC that
will supply an arm for improving diagnosis and manage-
ment of human HCC.* Correspondence: yongqian_shu@163.com
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© 2015 Huang et al.Long non-coding RNAs (LncRNAs) are non-protein
coding transcripts with a length greater than 200 nucleo-
tides. Accumulating evidence showed that lncRNAs par-
ticipated in cancer cells biological processes, such as cell
growth, cell metastasis, cell differentiation, and fate deci-
sion [2–4]. Additionally, many studies demonstrate that
lncRNAs play a critical role in tumorigenesis, and their
misexpression confers tumor initiation and cancer cell
growth and metastasis [5–7]. For example, lncRNA
HOTAIR is dysregulated in many cancers [8, 9]. More-
over, it could promote the invasion-metastasis cascade
in cancer cells by binding to PRC2 [8]. In a word, there
has been a heavy focus on the ways that lncRNAs con-
tribute to cancer development. However, their aberrant
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still not well-documented.
Among them, lncRNA CDKN2B antisense RNA 1
(ANRIL) is transcribed from the INK4b-ARF-INK4a
gene cluster in the opposite direction, which has been
identified as a genetic susceptibility locus shared associ-
ated by coronary disease, intracranial aneurysm, type 2
diabetes, and also cancers [10, 11]. Moreover, ANRIL
could be induced by ATM-E2F1 signaling pathway and
is required for the silencing of p15INK4B by recruiting
PRC2 [12, 13]. In our previous study, we found that
ANRIL was overexpressed and played an important role in
gastric carcinogenesis and NSCLC development [14, 15].
However, the functional role and underlying mechanism of
ANRIL in HCC remains unclear. Here we investigate the
relationship between ANRIL and HCC. We found that
ANRIL was up-regulated in HCC tissues than that in cor-
responding non-tumor tissues, and its up-regulation is re-
lated with tumor size and Barcelona Clinic Liver Cancer
(BCLC) stage. Moreover, ANRIL could regulate cell growth
both in vitro and in vivo via epigenetically silencing KLF2
by binding to PRC2. We also found that Sp1 could regu-
late the expression of ANRIL. Our results suggest that
Sp1-induced ANRIL can regulate KLF2 expression in the
epigenetic level and facilitate the development of lncRNA-
directed diagnostics and therapeutics of HCC.
Results
ANRIL is up-regulated in hepatocellular carcinoma tissues
and is associated with tumor size and BCLC stage
ANRIL expression was significantly up-regulated in 75.32 %
(58 of 77, fold ≧1.0) tumor tissues compared with nor-
mal counterparts (P < 0.01) (Fig. 1a, b). To understand
the significance of ANRIL overexpression in HCC, we
investigated the potential associations between ANRIL
expression and patients’ clinicopathological features.
Clinicopathological features of HCC patients are shown in
Table 1. Noticeably, high ANRIL expression was signifi-
cantly correlated with tumor size (P < 0.01) and advanced
BCLC stage (P < 0.01). However, ANRIL expression was
not associated with other parameters such as drinking
state (P = 0.932), age (P = 0.850), gender (P = 0.608), AFP
(P = 0.713), HBV (P = 0.713), and cirrhosis (P = 0.319)
in HCC.
ANRIL is up-regulated in HCC cell lines and could be
activated by transcript factor SP1
To investigate the functional role of ANRIL in HCC
cells, quantitative real-time polymerase chain reaction
(qRT-PCR) was used to detect the expression of ANRIL in
three HCC cell lines. As shown in Fig. 1c, three cell lines
(HepG2, HepG3B, MHCC-97H) expressed high levels of
ANRIL compared with the normal hepatic epithelium cell
line (L02). Previous study indicated that ANRIL expressioncould be activated by E2F1. In this study, we per-
formed bioinformatics analysis and found that there
are 13 SP1 binding sites in the ANRIL promoter region
(as shown in Table 2), which suggest that SP1 could also
regulate ANRIL transcription in HCC cells. Chromatin
immunoprecipitation (ChIP) assay showed that SP1 could
directly bind to ANRIL promoter regions (1081 bp) to si-
lence ANRIL transcription. In addition, overexpression of
SP1 in HCC cells could up-regulate ANRIL expression,
while knockdown of SP1 in HCC cells could down-regulate
ANRIL expression (as shown in Fig. 1d–k).
Knockdown of ANRIL inhibits HCC cell proliferation and
induces cell apoptosis in vitro
To investigate the potential role of ANRIL on HCC cell
proliferation, ANRIL siRNA was transfected into HepG2
and HepG3B cells. To ensure the efficiency of interfer-
ence and avoid off-target effects, we used a validated ef-
fective interference target sequence of ANRIL, according
to Kotake’s study [12]. qRT-PCR assays revealed that
ANRIL expression was significantly reduced after transfec-
tion with si-ANRIL (Fig. 2a). Then MTT assay showed
that knockdown of ANRIL expression significantly inhib-
ited cell proliferation both in HepG2 and HepG3B cells
compared with control cells (Fig. 2b). Similarly, the result
of colony formation assay revealed that clonogenic sur-
vival was significantly decreased following inhibition of
ANRIL both in HepG2 and Hep3B cell lines (Fig. 2c).
Next, flow cytometric analysis was performed to further
examine whether the effect of ANRIL on proliferation of
HCC cells by altering cell cycle progression or apoptosis.
The results revealed that the cell cycle progression of
HepG2/si-ANRIL and Hep3B/si-ANRIL cells was signifi-
cantly stalled at the G1–G0 phase compared with cells
transfected with si-NC (Fig. 2d). In addition, knockdown
of ANRIL could obviously induce cell apoptosis (Fig. 2e).
Effect of ANRIL on HCC cell migration and invasion
Migration and invasion is a significant aspect of cancer
progression, which involves the dissolution of extracellu-
lar matrix proteins and the migration of tumor cells into
contiguous tissues. To investigate whether ANRIL had a
direct functional role in cell invasion in HCC, we per-
formed transwell assays. The results showed that inhib-
ition of ANRIL could significantly impair HCC cells
migration and invasion ability when compared with con-
trol cells (Fig. 3).
ANRIL promotes HCC cell proliferation in vivo
To further determine whether ANRIL affects tumorigen-
esis, we injected HepG2 cells transfected with either empty
vector or sh-ANRIL into male nude mice. In consistent
with in vitro results, tumor growth in the sh-ANRIL group
was obviously slower than that in the empty vector group
Fig. 1 Relative ANRIL expression in HCC tissues and HCC cell lines and ANRIL was regulated by SP1. a Relative ANRIL expression in HCC tissues
(n = 77) compared with corresponding non-tumor tissues (n = 77). ANRIL expression was examined by qPCR and normalized to GAPDH expression.
Results were presented as ΔCT in tumor tissues relative to normal tissues. b ANRIL expression was classified into two groups. Positive ΔΔCT meant
high ANRIL expression. Negative ΔΔCT meant low ANRIL expression. c Relative ANRIL expression levels of HCC cell lines (HepG2, Hep3B, MHHC-97H)
compared with those of the normal hepatic epithelium cell line (L02). d ChIP-qPCR of SP1 occupancy and binding in the ANRIL promoter in HepG2
and Hep3B cells and IgG as a negative control. e The SP1 expression level was determined by qPCR when HepG2 cells transfected with si-SP1. f The
ANRIL expression level was determined by qPCR when HepG2 cells transfected with si-SP1. g The SP1 expression level was determined by qPCR when
Hep3B cells transfected with si-SP1. h The ANRIL expression level was determined by qPCR when Hep3B cells transfected with si-SP1. i The SP1
expression level was determined by qPCR when HepG2 cells transfected with EGFP-SP1. j The ANRIL expression level was determined by
qPCR when HepG2 cells transfected with EGFP-SP1. k The SP1 expression level was determined by qPCR when Hep3B cells transfected with
EGFP-SP1. l The ANRIL expression level was determined by qPCR when Hep3B cells transfected with EGFP-SP1.*P < 0.05, **P < 0.01
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weight in the sh-ANRIL group (0.260 ± 0.107 g) was
significantly lower than that in the control group
(0.442 ± 0.716 g) (P < 0.01) ((Fig. 4b). qRT-PCR analysis
was performed to detect the average expression of ANRIL
in tumor tissues selected from mice (Fig. 4c). Results dem-
onstrated that the average expression levels of ANRIL in
the sh-ANRIL group were lower than those in the empty
group. Moreover, we found that the tumors developed
from empty vector transfected cells showed a stronger
Ki-67 expression than that in tumors formed from sh-
ANRIL as detected by immunohistochemistry (IHC) ana-
lysis (Fig. 4d). These data further supported the role of
ANRIL in HCC cell growth and proliferation.ANRIL negatively regulates expression of KLF2
As previously reported, ANRIL could suppress p15 and
p21 expression by binding with PRC2. In the present
study, to investigate whether there are some other target
genes that may be regulated by ANRIL, we performed co-
expression analysis by using GSE45435 data from GEO
datasets. The results showed that Kruppel-like factor 2
(KLF2) may be a new target of ANRIL in HCC (as shown
in Fig. 5a). We also analyzed the KLF2 gene expression in
HCC by using GSE 56140. It showed that KLF2 was
down-regulated in HCC (as shown in Fig. 5b). And we
further found that knockdown of ANRIL expression could
up-regulate both KLF2 mRNA and protein expression
levels in HCC cells (Fig. 5c–e). Moreover, knockdown of
Table 1 Correlation between ANRIL expression and
clinicopathological characteristics in hepatocellular carcinoma
Clinical parameter ANRIL Chi-squared
test P value
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protein expression levels in HCC cells (Fig. 5f–k). We ex-
amined the ANRIL expression levels in HCC cell cyto-
plasm and nucleus distribution, and the results showed
that ANRIL expression is more located in nucleus (seen in
Fig. 5l, m). In addition, the results of RNA immunoprecip-
itation (RIP) assays revealed that ANRIL could directly
bind with PRC2 in HCC cells (seen in Fig. 5n, o). And
ChIP assays were performed to determine whether EZH2
could directly bind to KLF2 promoter regions to silence
KLF2 transcription. The results showed that EZH2 can
directly bind to KLF2 promoter regions (616 bp), while
knockdown of ANRIL expression decreased its binding
ability (seen in Fig. 5p, q). Then qRT-PCR analysis was
performed to detect the average expression of KLF2 intumor tissues from mice (Fig. 5r). Results demonstrated
that the average expression levels of KLF2 in the sh-
ANRIL group were higher than those in the empty group.
Finally, we found that the tumors developed from sh-
ANRIL-transfected cells showed a stronger KLF2 ex-
pression than that in tumors formed from empty vector
as detected by IHC analysis (Fig. 5s). These data indicated
that KLF2 was a new ANRIL target gene in HCC, and its
expression can be silenced by EZH2 which is recruited by
ANRIL to KLF2 promoter region and mediated H3K27
trimethylation modification.
Overexpression of KLF2 impairs HCC cell proliferation and
induces cell apoptosis
To determine whether KLF2 involved in ANRIL mediated
increased HCC cell proliferation, we up-regulated KLF2
expression in HCC cells by transfecting with a FLAG-
tagged KLF2 expression vector using the pCMV-Tag2B
vector (Stratagene, Santa Clara, CA, USA). The qRT-PCR
results showed that KLF2 expression is significantly up-
regulated in pCMV-Tag2B-KLF2-transfected HCC cells
when compared with control cells (Fig. 6a). Furthermore,
MTTassays and colony formation assay revealed that KLF2
overexpression inhibited HCC cell growth (Fig. 6b, c), and
flow cytometric analysis indicated that increased KLF2
expression induced cell apoptosis. These data suggest
that KLF2 partly involved in HCC cell proliferation
and apoptosis.
ANRIL negatively regulates expression of KLF2 by rescue
assays
Rescue assays were performed to determine whether ANRIL
regulates HCC cell proliferation via repressing KLF2 expres-
sion. HepG2 cells were co-transfected with si-ANRIL and
si-KLF2. The results of MTT and colony formation assay
indicated that co-transfection could partially rescue si-
ANRIL-impaired proliferation in HepG2 cells (Fig. 7a, b).
Western blotting showed the same results (Fig. 7c).
Discussion
In recent years, the discovery of lncRNAs, which have
emerged as a new and crucial layer of gene regulators, has
dramatically altered our understanding of the biology of
complex diseases including cancers [16, 17]. A large num-
ber of studies have shown that dysregulated expression of
lncRNAs participate in cancer progression and predict pa-
tients’ outcome [18–20]. For example, GAS5 can promote
the apoptosis of prostate cancer cells and its levels decline
as prostate cancer cells acquire castrate-resistance, so that
enhancing GAS5 expression may improve the effective-
ness of chemotherapies [6]. In HCC, HULC was the first
reported lncRNA that is specifically up-regulated [21, 22].
A number of lncRNAs, such as MVIH and URHC, have
been reported to be involved in HCC development and
Table 2 SP1 putative binding sites in the ANRIL promoter region by JASPAR
13 putative sites were predicted with these settings (90 %) in sequence named gi 568815589: 21992791–21994791
Model ID Model name Score Relative score Start End Strand Predicted site sequence
MA0079.3 SP1 11.960 0.931611173530848 1241 1251 1 TCTCCTCCTCC
MA0079.3 SP1 11.933 0.931271482620182 1244 1254 1 CCTCCTCCTCC
MA0079.3 SP1 11.615 0.927270678561222 1647 1657 1 GCACCGCCCCC
MA0079.3 SP1 11.673 0.928000384961913 1664 1674 1 TCTCCGCCCCG
MA0079.3 SP1 12.920 0.943689072576764 1702 1712 1 CGCCCGCCCCC
MA0079.3 SP1 10.466 0.912814943140641 1709 1719 1 CCCCCACCTTC
MA0079.3 SP1 14.400 0.962309166939219 1721 1731 1 CCCCCACCCCC
MA0079.3 SP1 11.514 0.925999982932433 1727 1737 1 CCCCCACCCCA
MA0079.3 SP1 13.360 0.949224776306143 1732 1742 1 ACCCCACCCCC
MA0079.3 SP1 10.179 0.909204154571706 1864 1874 1 CTCCCGCCTAC
MA0079.3 SP1 9.496 0.90061123264633 1882 1892 1 TTCCCGCCCTG
MA0079.3 SP1 14.400 0.962309166939219 1899 1909 1 CCCCCACCCCC
MA0079.3 SP1 10.467 0.912827524285481 1919 1929 1 TTCCCACCCTC
This type of analysis has a high sensitivity but abysmal selectivity. In other words, while true function will be detected in most cases, most predictions will
correspond to sites bound in vitro but with no function in vivo. A number of additional constraints of the analysis can improve the prediction; phylogenetic
footprinting is the most common. We recommend using the ConSite service, which uses the JASPAR datasets. The review Nat Rev Genet. 2004 Apr;5(4):276–87
gives a comprehensive overview of transcription binding site prediction [33]
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lncRNA ANRIL whose expression is significantly up-
regulated in HCC tissues compared with normal tissues.
Moreover, increased ANRIL expression was correlated
with HCC tumor size and BCLC stage, which suggests
that ANRIL may play a key role in HCC development and
progression.
Recently, several studies indicated that lncRNA ex-
pression could also be regulated by some transcript fac-
tors (TF), such as c-myc which could activate HOTAIR
transcription, and PVT-1 expression can be regulated by
p53 [24, 25]. ANRIL expression has been reported to be
regulated by a key TF E2F1 [13, 26]; however, in this
study, we performed bioinformatics analysis and found
that SP1 could also regulate ANRIL transcription in
HCC cells. ChIP assay also showed that SP1 could dir-
ectly bind to ANRIL promoter regions to silence ANRIL
transcription. In addition, overexpression of SP1 in HCC
cells could up-regulate ANRIL expression, while knock-
down of SP1 in HCC cells could down-regulate ANRIL
expression. These data showed that ANRIL expression
could also be regulated by SP1 in HCC cells, which sug-
gests that one lncRNA may be simultaneously regulated
by multiple different transcript factors.
As is known, lncRNAs participated in cancer cells’ bio-
logical function, and we found that knockdown of ANRIL
could impair HCC cell proliferation and invasion and in-
duce cell apoptosis both in vitro and in vivo. These data
suggests that lncRNA ANRIL contributes to HCC devel-
opment via regulation of cell proliferation and apoptosis.
A completely different mode of action is executed by thelncRNA ANRIL to block the activity of tumor suppressor
genes. For example, ANRIL interacts with SUZ12 (a sub-
unit of the PRC2) and recruits the complex to repress the
expression of p15 (INK4B), a well-known tumor suppres-
sor gene [13]. A similar study identified chromobox
homolog 7 (CBX7), a subunit of the polycomb repressive
complex 1 (PRC1) as molecular interaction partner of
ANRIL, which results in the recruitment of PRC1 to the
p16(INK4A)/p14(ARF) locus and silencing of this gene
locus by H3K27 trimethylation [10]. However, we found
that ANRIL could bind with both EZH2 and SUZ12 in
HCC cells. Furthermore, bioinformatics analysis indicated
that KLF2 could be a new ANRIL downstream target, and
knockdown of ANRIL, EZH2 and SUZ12 expression in-
deed both up-regulated KLF2 expression levels in HCC
cells. In addition, ChIP assays also demonstrated that
EZH2 could directly bind to KLF2 promoter region and
inhibition of ANRIL decreased its binding ability. Our re-
sults indicated that ANRIL could repress KLF2 transcrip-
tion by binding with EZH2 and SUZ12 and recruitment of
PRC2 to the KLF2 gene locus in HCC cells.
The Kruppel-like factor (KLF) family which consists of
a set of transcription factors that have been identified in
diverse organisms functions in cell differentiation and
proliferation [27]. They have been identified as suppres-
sors or activators of different genes in a cell type and
promoter-dependent manner [28]. KLF2 is one of the
critical members due to its tumor suppressor function in
tumors [29, 30]. Moreover, previous study showed that
EZH2 could directly bind to KLF2 promoter and silence
of KLF2 expression result in blocking the tumor-
Fig. 2 (See legend on next page.)
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Fig. 2 Effects of knockdown of ANRIL on HCC cell viability and apoptosis in vitro. a The ANRIL expression level was determined by qPCR when
HepG2 and Hep3B cells transfected with si-ANRIL. b MTT assays were used to determine the cell viability for si-ANRIL-transfected HepG2 and
Hep3B cells. Values represented the mean ± s.d. from three independent experiments. c Colony-forming assays were conducted to determine the
proliferation of si-ANRIL-transfected HepG2 and Hep3B cells. d Flow cytometry assays were performed to analyze the cell cycle progression when
HCC cells transfected with si-ANRIL 24 h later. The bar chart represented the percentage of cells in G0/G1, S, or G2/M phase, as indicated. e Flow
cytometry assays were performed to analyze the cell apoptosis when HCC cells transfected with si-ANRIL 48 h later. *P < 0.05, **P < 0.01
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p21 [31]. Our data also showed that ANRIL could take
part in HCC cell proliferation by silencing KLF2 tran-
scription, and KLF2 overexpression further led to the
decreased HCC cell proliferation and increased cell apop-
tosis. Furthermore, we performed rescue assays to deter-
mine whether ANRIL regulates HCC cell proliferation via
repressing KLF2 expression. The results of MTT and
colony formation assay indicated that co-transfection
could partially rescue si-ANRIL-impaired proliferation in
HepG2 cells. These data indicate that ANRIL promotes
HCC cell proliferation through the down-regulation of
KLF2 expression. Our results suggested that lncRNA, es-
pecially ANRIL, may influence the same cell biological
function via regulating different target genes depending
on different cancer cells.
Conclusion
In summary, the expression of ANRIL was significantly
up-regulated in HCC tissues and cells, suggesting that
its overexpression may be an important factor for HCC
progression. We showed that ANRIL may regulate the
proliferation ability of HCC cells partially through silen-
cing of the KLF2 by binding with PRC2, which suggested
that lncRNAs contribute to different cancer cells’ bio-
logical function through regulating different genes. Fur-
ther insights into the functional and clinical implications
of ANRIL and its targets, which are identified as KLF2,
may contribute to the understanding of HCC pathogen-
esis and facilitate the development of lncRNA-directed
diagnostics and therapeutics against this disease.
Materials and methods
Patient data and tissue samples
A total of 77 fresh HCC tissue samples and matched
normal adjacent tissue samples were selected from pa-
tients who underwent resection of HCC at Huai’an First
People’s Hospital, Nanjing Medical University (Huai’an,
China). The HCC diagnosis was histopathologically con-
firmed. None of the patients received preoperative ther-
apy. Data from all subjects were obtained from medical
records, pathology reports, and personal interviews with
the subjects. The collected data included gender, age,
drinking state, the history of HBV and cirrhosis, and HCC
features (e.g., tumor size, stage). HCC clinical stage was
determined according to the BCLC staging classificationbased on the article by Bruix et al. [32]. The clinical infor-
mation for all of the samples is detailed in Table 1. Fresh
samples were snap-frozen in liquid nitrogen immediately
after resection and stored at −80 °C. Matched non-tumor
specimens were obtained from a part of the resected spe-
cimen that was farthest from the tumor.
Ethical approval of the study protocol
This study was conducted according to the principles
expressed in the Declaration of Helsinki. Tissue specimen
collections were made with full informed consent of all
patients following institutional ethical guidelines that were
reviewed and approved by Huai’an First People’s Hospital,
Nanjing Medical University (Huai’an, China).
Cell culture
Human HCC cell lines (HepG2, Hep3B, MHCC-97H)
and one normal hepatic epithelial cell line (L02, control)
were provided by Dr Beicheng Sun from the Department of
Hepatopancreatobiliary, First Affiliated Hospital, Nanjing
Medical University (Nanjing City, Jiangsu Province, People’s
Republic of China). All cell lines were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (GIBCO-BRL) medium
supplemented with 10 % fetal bovine serum (FBS) at 37 °C
in 5 % CO2.
RNA extraction and qRT-PCR analysis
The total RNA was extracted from tissues or cells with
TRIzol reagent (Invitrogen, Grand Island, NY, USA), ac-
cording to the manufacturer’s protocol. One microgram
total RNA was reverse transcribed in a final volume of
20 μL under standard conditions using PrimeScript RT
Reagent Kit with gDNA Eraser (Takara, Dalian, China;
RR047A). After the RT reaction, 1 μL of the comple-
mentary DNA was used for subsequent qRT-PCR reac-
tions (SYBR Premix Ex Taq, TaKaRa) following the
manufacturer’s protocol. The results were normalized to
the expression of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). The qRT-PCR and data collection
were carried out on ABI 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA), and results
were analyzed and expressed relative to threshold cycle
(CT) values, and then converted to fold changes. All pri-
mer sequences are summarized in Additional file 1:
Table S1.
Fig. 3 Effect of ANRIL on HCC cell migration and invasion. a, b, e The results showed that inhibition of ANRIL could significantly impair HepG2
cell migration and invasion ability when compared with control cells. c, d, f The results showed that inhibition of ANRIL could significantly impair
Hep3B cell migration and invasion ability when compared with control cells. **P < 0.01
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Fig. 4 Effects of down-regulation of ANRIL on tumor growth in vivo. a Tumors from mice 16 days after injection of HepG2 cells stably transfected
with sh-ANRIL or empty vector. b The tumor volume was calculated every 4 days after injection of HepG2 cells stably transfected with sh-ANRIL
or empty vector. Points, mean (n = 5); bars indicate s.d. c Tumor weights are represented as means of tumor weights ± s.d. d qPCR analysis of
ANRIL expression in tumor tissues formed from HepG2/sh-ANRIL, HepG2/empty vector. e Tumors developed from sh-ANRIL-transfected HepG2
cells showed lower Ki-67 protein levels than tumors developed by control cells. Left: H & E staining; right: immunostaining. *P < 0.05, **P < 0.01
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HCC cell lines were transfected with specific siRNA oli-
gonucleotides. To avoid off-target effects and ensure the
efficiency of interference, we used an indeed effective
interference target sequence of ANRIL, according to the
previous study [12]. EZH2 and SUZ12 siRNA were pur-
chased from Realgene (Nanjing, China). Non-specific siRNA
(si-NC) and si-ANRIL were purchased from Invitrogen.
Typically, cells were seeded at six-well plates and then
transfected the next day with specific siRNA (100 nM)
and control siRNA (100 nM) by using Lipofectamine
RNAi MAX, according to the manufacturer’s protocol
(Invitrogen). EGFP-SP1 was purchased from Add gene.
Plasmid vectors (EGFP-SP1, sh-ANRIL pCMV-Tag2B-
FLAG-KLF2 and empty vector) for transfection were pre-
pared using DNA Midiprep or Midiprep kits (Qiagen,
Hilden, Germany) and transfected into HepG2 and
Hep3B cells.
Cell proliferation assays
Cell proliferation was monitored by Cell Proliferation
Reagent Kit I (MTT) (Roche, Basel, Switzerland). Thetransfected cells were plated in 96-well plates (3000
cells/well). Cell proliferation was determined every 24 h
following the manufacturer’s protocol. For the colony
formation assay, 500 transfected cells were placed into
each well of a six-well plate and maintained in DMEM
containing 10 % FBS for 12 days, replacing the medium
every 4 days. Colonies were fixed with methanol and
stained with 0.1 % crystal violet (Sigma-Aldrich, St. Louis,
MO, USA) in PBS for 15 min. The colony formation
was determined by counting the number of stained col-
onies. Triplicate wells were measured in each treatment
group.
Flow cytometry for cell cycle analysis
HepG2 or Hep3B cells for cell cycle analysis were col-
lected 24 h after transfected with si-ANRIL or respective
control and 48 h after transfected with pCMV-Tag2B-
KLF2 or empty vector. Then cells were stained with pro-
pidium iodide (PI) using the CycleTEST™ PLUS DNA
Reagent Kit (BD Biosciences) following the protocol and an-
alyzed by FACScan. The percentage of the cells in G0/G1,
S, and G2/M phase were counted and compared.
Fig. 5 ANRIL could silence KLF2 expression. a Co-expression analysis by using GSE45435 data from GEO datasets. b The KLF2 gene expression in
HCC by using GSE 56140. c–e The levels of KLF2 mRNA and protein were detected by qPCR and Western blotting when HepG2 and Hep3B cells
transfected with si-ANRIL, and results are expressed relative to the corresponding values for control cells. f–h The levels of KLF2 mRNA and protein
were detected by qPCR and Western blotting when HepG2 and Hep3B cells transfected with si-EZH2, and results are expressed relative to the
corresponding values for control cells. i–k The levels of KLF2 mRNA and protein were detected by qPCR and Western blotting when
HepG2 and Hep3B cells transfected with si-SUZ12, and results are expressed relative to the corresponding values for control cells. l, m
ANRIL expression levels in cell cytoplasm or nucleus of HCC cell lines Hep3B and HepG2 were detected by qPCR. n, o RIP with rabbit
monoclonal anti-EZH2, anti-SUZ12, anti-SNRNP70, and preimmune IgG from HepG2 and Hep3B cell extracts. RNA levels in immunoprecipitates
were determined by qPCR. Expression levels of ANRIL RNA were presented as fold enrichment in EZH2 and SUZ12 relative to IgG immunoprecipitates;
relative RNA levels of U1 snRNA in SNRNP70 relative to IgG immunoprecipitates were used as positive control. p, q ChIP-qPCR of EZH2 occupancy and
H3K27-3me binding in the KLF2 promoter in HepG2 cells and IgG as a negative control; ChIP-qPCR of EZH2 occupancy and H3K27-3me binding in the
KLF2 promoter in HepG2 cells transfected with ANRIL siRNA (48 h) or scrambled siRNA. r The KLF2 expression level was determined by qPCR in mice
tumors formed from HepG2/sh-ANRIL, HepG2/empty vector. s Tumors developed from sh-ANRIL-transfected HepG2 cells showed higher KLF2 protein
levels than tumors developed by control cells. **P < 0.01
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HepG2 or Hep3B cells transfected with si-ANRIL, pCMV-
Tag2B-KLF2, or respective control were harvested 48 h
and then collected. After the double staining with FITC-
Annexin V and PI was done using the FITC Annexin V
Apoptosis Detection Kit (BD Biosciences) according to
the manufacturer’s protocol, the cells were analyzed with
a flow cytometry (FACScan®; BD Biosciences) equipped
with a CellQuest software (BD Biosciences). Cells were
discriminated into viable cells, dead cells, early apoptotic
cells, and apoptotic cells, and then the relative ratio ofearly apoptotic cells was compared to control transfectant
from each experiment.
Cell migration and invasion assays
HepG2 or Hep3B cells transfected with si-ANRIL or re-
spective control were harvested 48 h and then collected. For
the migration assays, 5 × 104 cells in serum-free medium
were placed into the upper chamber of an insert (8 μm
pore size, Millipore). For the invasion assays, 1× 105 cells
in serum-free medium were placed into the upper cham-
ber of an insert coated with Matrigel (Sigma-Aldrich).
Fig. 6 (See legend on next page.)
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Fig. 6 Overexpression of KLF2 expression inhibits HepG2 cell proliferation and improves apoptosis. a The mRNA level of KLF2 in HepG2 and
Hep3B cells transfected with pCMV-Tag2B-KLF2 or empty vector was detected by qPCR. b, c MTT assays and colony-forming assays were used to
determine the cell viability for pCMV-Tag2B-KLF2-transfected or empty vector-transfected HepG2 and Hep3B cells. Values represent the mean ±
s.d. from three independent experiments. d Apoptosis was determined by flow cytometry. UL necrotic cells, UR terminal apoptotic cells, LR early
apoptotic cells. *P < 0.05, **P < 0.01
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chamber. After incubation for 24 h, we removed the cells
remaining on the upper membrane with cotton wool.
Cells that had migrated or invaded through the membrane
were fixed with methanol, stained with 0.1 % crystal violet,
imaged, and counted using an IX71 inverted micro-
scope (Olympus, Tokyo, Japan). Experiments were re-
peated three times.
Xenograft study
HepG2 cells were transfected with sh-ANRIL or Scramble
using Lipofectamine 2000 (Invitrogen). Forty-eight hours
later, cells were collected and injected into either side of the
posterior flank of the male BALB/c nude mice (4–5 weeks
old). Mice were purchased from Shanghai Experimental
Animal Center of the Chinese Academy of Sciences. The
tumor volumes and weights were measured every 4 days in
mice from the control (five mice) or sh-ANRIL (five mice)
groups, and tumor volumes were calculated by using theFig. 7 ANRIL negatively regulates expression of KLF2 by rescue assays. a, b
HepG2 cells transfected with si-NC and si-ANRIL and co-transfected with
independent experiments. c MTT assays were used to determine the c
co-transfected with siANRIL and si-KLF2. Values represent the mean ± s.
protein levels were determined by Western blotting when HepG2 cells
and si-KLF2. *P < 0.05, **P < 0.01equation V = 0.5 ×D × d2 (V, volume; D, longitudinal diam-
eter; d, latitudinal diameter). Sixteen days after injection,
the mice were killed and tumors were collected for fur-
ther study (weight measure, RNA extraction, and IHC).
This study was carried out strictly in accordance with
the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Committee on
the Ethics of Animal Experiments of Nanjing Medical
University.
Immunohistochemistry
Tumors from mice were immunostained for HE, ki-67,
and KLF2. The signal was amplified and visualized with
3′-diaminobenzidine chromogen, followed by counter-
staining with hematoxylin. Expression was considered to
be positive when 50 % or more tumor cells were stained.
Anti-ki-67 (1:50) and anti-KLF2 (1:50) were purchased
from R&D company.Colony-forming assays were used to determine the cell viability for
siANRIL and si-KLF2. Values represent the mean ± s.d. from three
ell viability for HepG2 cells transfected with si-NC and si-ANRIL and
d. from three independent experiments. d, e The levels of KLF2
transfected with si-NC and si-ANRIL and co-transfected with siANRIL
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Cells were lysed by using mammalian protein extraction
reagent RIPA (Beyotime, Haimen, China) supplemented
with protease inhibitors cocktail (Roche). Fifty micro-
grams of the protein extractions were separated by 10 %
SDS-PAGE transferred to 0.22-mm nitrocellulose (NC)
membranes (Sigma-Aldrich) and incubated with specific
antibodies. The autoradiograms were quantified by densi-
tometry (Quantity One software, Bio-Rad, Hercules, CA,
USA). Anti-KLF2 was purchased from Sigma (1:1000). Re-
sults were normalized to the expression GAPDH (mouse
anti-GAPDH) (Sigma (1:1000)).
Subcellular fractionation location
The separation of the nuclear and cytosolic fractions of
HCC cell lines was performed according to the protocol
of the PARIS Kit (Life Technologies, Carlsbad, CA, USA).
Chromatin immunoprecipitation assays
The ChIP assays were performed by using EZ-ChIP KIT
according to the manufacturer’s instruction (Millipore,
Billerica, MA, USA). HepG2 and Hep3B cells were treated
with formaldehyde and incubated for 10 min to gener-
ate DNA-protein cross-links. Cell lysates were then soni-
cated to generate chromatin fragments of 200–300 bp and
immunoprecipitated with EZH2, SUZ12, and H3K27me3-
specific antibody (CST) or IgG as control. Precipitated
chromatin DNA was recovered and analyzed by qRT-
PCR.
RNA immunoprecipitation
RIP experiments were performed by using a Magna RIP
RNA-Binding Protein Immunoprecipitation Kit (Millipore)
according to the protocol. Antibody for RIP assays of
EZH2 and SUZ12 was purchased from Millipore.
Statistical analysis
All statistical analyses were performed by using SPSS 17.0
software (IBM, Chicago, IL, USA). The significance of dif-
ferences between groups was estimated by the Student t
test, Wilcoxon test, or χ2 test. Two-sided P values were
calculated, and differences were considered to be statisti-
cally significant at P < 0.05. Kendall’s Tau-b and Pearson
correlation analyses were used to investigate the correl-
ation between ANRIL and KLF2 expressions.
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